Cytovale任命Rhonda Collins为首席护理官-动脉网

Cytovale Names Rhonda Collins Chief Nursing Officer

CISION 等信源发布 2025-03-18 20:59



可切换为仅中文







Seasoned nurse executive and health IT leader to drive expansion of nurse-driven sepsis protocol leveraging IntelliSep

资深护士主管和健康IT领导者将推动利用IntelliSep的护士主导的败血症协议的扩展。

rapid detection solution

快速检测解决方案

SAN FRANCISCO

旧金山

，

March 18, 2025

2025年3月18日

/PRNewswire/ --

Cytovale

细胞谷

, a commercial-stage medical diagnostics company, today announced the appointment of

，一家处于商业化阶段的医疗诊断公司，今天宣布任命

Rhonda Collins

兰达·柯林斯

, DNP, RN, FAAN, as the company's first chief nursing officer (CNO). A former nurse, seasoned hospital executive and leader in healthcare IT, Collins will oversee Cytovale's clinical consultant team as they engage with hospital executives around the country to implement nurse-driven sepsis protocols with the company's rapid sepsis detection solution, .

，DNP，注册护士，FAAN，担任该公司的首位首席护理官（CNO）。科林斯曾是一名护士，资深医院主管，并在医疗信息技术领域具有领导地位，她将负责监督Cytovale的临床顾问团队，与全国各地的医院主管合作，推动以公司快速败血症检测解决方案为基础的、由护士主导的败血症协议实施工作。

IntelliSep

。

'We've seen strong clinical improvements – including a 30% reduction in risk-adjusted mortality – when hospitals use IntelliSep as part of a nurse-driven sepsis protocol in their emergency departments. We're now looking to bring that same protocol to hospitals across the U.S.,' said

“我们已经看到了显著的临床改善——包括在医院急诊科使用 IntelliSep 作为护士主导的败血症协议的一部分时，经风险调整后的死亡率降低了 30%。我们现在正计划将同样的协议推广到美国各地的医院，”

Ajay Shah

阿贾伊·沙阿

, Cytovale co-founder and CEO. 'Rhonda, with her deep understanding of nursing workflows and implementing new technologies, will be instrumental in helping more hospitals develop effective sepsis protocols that empower the nursing staff and benefit their patients.'

Cytovale联合创始人兼首席执行官表示：“Rhonda凭借其对护理工作流程的深刻理解以及实施新技术的能力，将在帮助更多医院制定有效的败血症方案、提升护理人员能力及造福患者方面发挥关键作用。”

A registered nurse for over three decades, Dr. Collins was a hospital executive before continuing her evolution to become a leader in healthcare IT. She comes to Cytovale from Kontakt.io, where she served as CNO. She also served in the same role at Vocera Communications, where she made it her mission to ensure technology conformed to the real-world needs of hospitals.

拥有超过三十年注册护士经验的柯林斯博士在继续发展成为医疗信息技术领域的领导者之前，曾担任医院高管。她从Kontakt.io加入Cytovale，此前在该公司担任首席护理官（CNO）。她还曾在Vocera Communications担任同样的职务，在那里她致力于确保技术符合医院的实际需求。

Throughout her career – including executive roles at Artisight, Fresenius-Kabi, Masimo Corporation, CareFusion and .

在她的职业生涯中——包括在Artisight、Fresenius-Kabi、Masimo Corporation、CareFusion等公司担任高管职务。

Baylor University

贝勒大学

Medical Center – Dr. Collins established herself as a leader in nurse innovation, redesigning clinical workflows and advocating for policy that puts patient safety and quality first. In 2019, Dr. Collins was named a fellow by the American Academy of Nursing, which recognized her extraordinary contributions to nursing and healthcare throughout her career.

医疗中心——柯林斯博士通过重新设计临床工作流程和倡导以患者安全和质量为先的政策，确立了自己在护士创新领域的领导地位。2019年，柯林斯博士被美国护理科学院授予院士称号，以表彰她职业生涯中对护理和医疗保健做出的非凡贡献。

She was named one of .

她被评为其中之一。

Becker's Hospital Review's

贝克尔医院评论的

Women to Watch in Health IT for four consecutive years and received the Outstanding Contribution of the Year award from Women in IT in 2021.

连续四年入选值得关注的健康IT女性，并在2021年获得IT女性年度杰出贡献奖。

'Cytovale is solving one of the most difficult conditions nurses face. Sepsis is a deadly reaction to infection with unclear symptoms that can be a challenge to diagnose. The stakes are incredibly high – with the risk of death skyrocketing

Cytovale正在解决护士面临的最困难问题之一。败血症是对感染的一种致命反应，其症状不明确，诊断起来颇具挑战性。风险非常高——死亡风险急剧上升。

as much as 8% every hour

每小时高达8%

sepsis goes untreated. Having a rapid, accurate test to diagnose or rule out sepsis is critical,' Dr. Collins said. 'Other emergent conditions, like STEMI and stroke, have nurse-driven protocols and there has been a real need for a solution that can quickly determine sepsis risk and put patients on the right treatment path.

“如果脓毒症得不到治疗，后果很严重。拥有一种快速、准确的检测方法来诊断或排除脓毒症至关重要，”柯林斯博士说。“其他紧急情况，如STEMI和中风，都有护士主导的协议，迫切需要一种能够快速确定脓毒症风险并让患者走上正确治疗路径的解决方案。”

I'm excited to work with nursing leadership around the country as they adopt IntelliSep technology and improve patient care in their hospitals.'.

我期待与全国各地的护理领导合作，因为他们采用IntelliSep技术，并改善其医院的患者护理。

Dr. Collins joins Cytovale's executive team, alongside recently

Collins博士加入Cytovale的执行团队，与最近的

named Chief Commercial Officer

被任命为首席商务官

Dave Vort

戴夫·沃尔特

, to help give more hospital emergency departments across the U.S. access to the life-saving IntelliSep technology.

，帮助美国更多的医院急诊部门获得拯救生命的IntelliSep技术。

About Cytovale

关于Cytovale

Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale's U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, IntelliSep

Cytovale 致力于通过开创早期检测技术来改善患者护理，这些技术评估免疫激活，以加快从分诊到挽救生命的治疗所需的时间。Cytovale 的美国食品和药物管理局批准的快速败血症诊断系统 IntelliSep

, leverages machine learning and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis. IntelliSep measures the dysregulated immune system response to infection that would indicate sepsis and generates results in about eight minutes using a standard blood draw.

，利用机器学习和先进的微流体技术，为急诊科临床医生提供一种客观且高度敏感的脓毒症早期检测工具。IntelliSep 通过测量感染引发的免疫系统失调反应来判断是否存在脓毒症，并通过标准抽血在约八分钟内生成结果。

Cytovale is based in .

Cytovale 总部位于。

San Francisco

旧金山

and venture-backed by Norwest Venture Partners, Sands Capital and Global Health Investment Corporation (GHIC). For more information, visit

并由 Norwest Venture Partners、Sands Capital 和全球健康投资公司 (GHIC) 提供风险投资支持。欲了解更多信息，请访问

www.cytovale.com

and follow Cytovale on

并关注Cytovale

领英

and